| Previous Close | 82.58 |
| Open | 82.42 |
| Bid | 71.12 x 1000 |
| Ask | 71.74 x 44000 |
| Day's Range | 82.30 - 83.26 |
| 52 Week Range | 66.72 - 92.97 |
| Volume | 850,217 |
| Avg. Volume | 2,343,007 |
| Market Cap | 101.63B |
| Beta | 0.74 |
| PE Ratio (TTM) | 11.51 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 3.30 (3.49%) |
| Ex-Dividend Date | 2017-05-16 |
| 1y Target Est | N/A |
- Market Realist•1 hour ago
Sanofi Genzyme Continues Driving Revenue Growth in 2Q17
In 2Q17, Sanofi Genzyme (SNY) reported revenue growth of 13.5% to 1.7 billion euros. Considering a constant structure and constant exchange rates, the growth was 14.4%. Sanofi Genzyme, which includes product ...
- Market Realist•3 hours ago
Sanofi’s Revenue Growth in 2Q17
At constant exchange rates, Sanofi (SNY) reported revenue growth of ~5.5% between 2Q16 and 2Q17, with revenue rising to 8.7 billion euros from 8.1 billion euros. The above chart shows Sanofi’s…
- Zacks•17 hours ago
Spectrum (SPPI) Initiates Phase II Study for Cancer Drug
Spectrum Pharmaceuticals, Inc. (SPPI) initiated the registrational phase III study of qapzola in patients with non-muscle invasive bladder cancer (NMIBC) as per the FDA's requirement.
